A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
Nom du journal : Gynecol Oncol
Année : 2008
Volume : 108
Page de départ : 42
Page de fin : 46